To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT ID: NCT00552305
Last Updated: 2018-07-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
370 participants
INTERVENTIONAL
2001-08-31
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00522275
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655486
Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
NCT00530855
Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures
NCT00515619
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655551
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lacosamide
50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
lacosamide
50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lacosamide
50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Meets withdrawal criteria for parent trial or experiencing ongoing serious adverse event.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Englewood, Colorado, United States
Gainesville, Florida, United States
Hollywood, Florida, United States
Miami, Florida, United States
Ponte Vedra Beach, Florida, United States
Chicago, Illinois, United States
Springfield, Illinois, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
Wichita, Kansas, United States
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
Baltimore, Maryland, United States
Frederick, Maryland, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
Saint Paul, Minnesota, United States
Chesterfield, Missouri, United States
St Louis, Missouri, United States
Somerset, New Jersey, United States
New York, New York, United States
Durham, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Irving, Texas, United States
Lubbock, Texas, United States
Wichita Falls, Texas, United States
Bennington, Vermont, United States
Charlottesville, Virginia, United States
Marshfield, Wisconsin, United States
Milwaukee, Wisconsin, United States
Bonn, , Germany
Erlangen, , Germany
Kehl Kork, , Germany
Schwalmstedt-Treysa, , Germany
Budapest, , Hungary
Zalaegerszeg, , Hungary
Kaunas, , Lithuania
Vilnius, , Lithuania
Poznan, , Poland
Gothenburg, , Sweden
Stockholm, , Sweden
Bern/Biel, , Switzerland
Zurich, , Switzerland
Bucks/London, , United Kingdom
Glasgow, , United Kingdom
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rosenfeld W, Fountain NB, Kaubrys G, Ben-Menachem E, McShea C, Isojarvi J, Doty P; SP615 Study Investigators. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy Behav. 2014 Dec;41:164-70. doi: 10.1016/j.yebeh.2014.09.074. Epub 2014 Oct 27.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP0615
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.